Committee OKs Retrospective Studies, But With Caveats
FDA's Oncologic Drugs Advisory Committee agreed that retrospective studies can be used to support predictive biomarkers. The agency convened the meeting in hopes of coming away with guidance on how to assess forthcoming applications to restrict therapies to patients, using predictive biomarkers
You may also be interested in...
The sensitivity and specificity of the target identification could determine size of the off-target population, CDER senior statistical advisor Robert O’Neill says at DIA/FDA meeting on revitalizing R&D.
A Center for Devices and Radiological Health representative tells a conference on drug/diagnostic co-development that it doesn’t matter how well designed a study for a therapeutic agent is if the accompanying biomarker-targeted test is not reliable and uniformly implemented.
FDA’s proposed process for qualifying drug development tools allows for the convening of advisory committee meetings or other public discussions about complicated submissions involving proposed biomarkers or patient-reported outcome instruments.